Day 3 | Session 8 | Concurrent |

Managing the Menopause – what’s in RANZCOG’s new guideline

Speaker 1

blurb

Speaker 1
Job title

bio

Speaker 2

blurb

Speaker 2
Job title

bio

Long term outcomes of menopausal hormone therapy use

The Women’s Health Initiative study (WHI) began recruitment in 1993. This was the first RCT to evaluate the benefits and risks of MHT for chronic disease prevention. When the study was stopped the women using estrogen V progestogen had used it for 5.6 years and women using estrogen only therapy had 7.2 years of use. We now have 20 year follow up for these women.

This presentation will discuss the clinical implications of this follow up and compare the risk/benefit profile of the use of both of these regimens of MHT for the management of vasomotor symptoms in younger women.

Associate Professor Helen Roberts
Menopause Consultant
Greenlane Clinical Centre, Auckland Hospital

Following her medical degree at Trinity College, Dublin, Helen Roberts worked in hospitals in Ireland then London. In 1983, she joined New Zealand Family Planning, becoming the Medical Director and National Medical Spokesperson from 1988-1992. In 1991, she completed the MPH at Yale University and on her return took up an academic position in the Department of Obstetrics and Gynaecology, University of Auckland. where she was involved in Cochrane reviews of MHT. Helen was Associate Professor of Women’s Health until retirement. 

At present, Helen continues working at the contraception and menopause clinic at Greenlane Clinical Centre and has clinics in abortion medicine at Epsom Day Unit.